OCT 11, 2017 09:00 AM PDT
Personalizing Melanoma Management with Molecular Diagnostics
Presented at the Cancer Research & Oncology 2017 Virtual Event
CONTINUING EDUCATION (CME/CE/CEU) CREDITS: P.A.C.E. CE | Florida CE
1 1 8

Speakers:
  • Chief Medical Officer at Castle Biosciences, Baylor College of Medicine
    Biography
      Dr. Monzon is a molecular pathologist with extensive experience translating novel genomic technologies into clinical molecular tests. Most recently, he served as Medical Director of Oncology and Medical Director of Latin America at Invitae Corporation, a provider of genetic diagnostics for hereditary disorders. Previously, Dr. Monzon served in several successive roles at Baylor College of Medicine, including Director of Pathology at its Cancer Genetics Laboratory. Earlier in his career, he led studies at the University of Pittsburgh on prostate and renal cancer genomics as well as the validation of one of the first gene expression clinical assays for the diagnosis of tumors of unknown origin. He earned his M.D. from the Universidad Nacional Autónoma de México, and is board-certified by the American Board of Pathology in anatomic, clinical and molecular genetic pathology. Dr. Monzon is the 2016 President-Elect of the Association for Molecular Pathology.

    Abstract:

    More and more decisions will center on the ability to molecularly characterize a disease. So the molecular diagnostic laboratory will have a pivotal role. What does that look like? Will we be able to maintain an environment where we have academic laboratories doing a good chunk of innovation and development that then can get translated into either reference laboratories or tests being done at local laboratories within the academic core and even community hospitals? The ecosystem that exists now encourages innovation to happen quickly and get those tests quickly into the hands of the clinical laboratories and make them accessible to patients. So the question is can we maintain this ecosystem when we overlay regulatory pressures, and financial or reimbursement pressures.


    Show Resources
    Loading Comments...